SCHEMBL7659283

SCHEMBL7659283

CCOc1ccc(Cn2c(C)nc3c(C(=O)O)cccc32)c(Cl)c1

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PIK3C2B O00750 8/20 0.47
ALOX5AP P20292 1/20 0.44
PIK3CB P42338 3/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
KDM4E B2RXH2 1/20 0.42
ALDH1A1 P00352 1/20 0.42
CYP1A2 P05177 1/20 0.42
HPGD P15428 1/20 0.42
TSHR P16473 1/20 0.42
HSD17B10 Q99714 1/20 0.42
LMNA P02545 1/20 0.41
NOTUM Q6P988 1/20 0.40
PIK3CD O00329 1/20 0.39
PIK3R1 P27986 1/20 0.39
DCTPP1 Q9H773 2/20 0.39
PPARG P37231 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6171656 0.85 PIK3C2B (0.51) PIK3C2BALOX5APPIK3CBSMN1; SMN2ALDH1A1
SCHEMBL7656112 0.85 LMNA (0.41) PIK3C2BSMN1; SMN2KDM4EALDH1A1CYP1A2
SCHEMBL7193408 0.83 PIK3C2B (0.42) PIK3C2BALOX5APPIK3CBDCTPP1PPARG
SCHEMBL6499333 0.83 BCL2 (0.50) PIK3C2BALOX5AP
SCHEMBL7196400 0.83 PIK3C2B (0.40) PIK3C2BPIK3CBDCTPP1PPARG
SCHEMBL7200216 0.82 PIK3C2B (0.41) PIK3C2BPIK3CBSMN1; SMN2DCTPP1
SCHEMBL6498814 0.81 S1PR1 (0.39) PIK3C2BDCTPP1PPARG
SCHEMBL6488966 0.80 RXRA (0.41) PIK3C2BALOX5APSMN1; SMN2DCTPP1PPARG
SCHEMBL6168359 0.80 LMNA (0.54) PIK3C2BSMN1; SMN2KDM4EALDH1A1CYP1A2
SCHEMBL6489353 0.79 PIK3C2B (0.38) PIK3C2BALOX5APSMN1; SMN2LMNADCTPP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6420409-B1 GLUCOSE TOLERANCE, DIABETES,INSULIN RESISTANCE, POLYCYSTIC OVARY SYNDROME, HYPERLIPIDEMIA, ATHEROSCLEROSIS, CARDIOVASCULAR DISORDERS, HYPERGLYCEMIA, HYPERTENSION, STENOCARDIA, PULMONARY HYPERTENSION, CONGESTIVE HEART FAILURE, FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-07-16 US disclosed